Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas
E. Ray Dorsey, Joel P. Thompson, Melisa Carrasco et al. · 2009
Read Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas by E. Ray Dorsey, Joel P. Thompson, Melisa Carrasco et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0007015.txt.
Description
E. Ray Dorsey, Joel Thompson, Melisa Carrasco, and colleagues audited research spending in PLOS ONE in 2009. They estimated United States biomedical research funding by disease area. Then they set that funding against the burden each disease causes. Finally, they counted the new drug approvals that followed from the investment.
Their window ran from 1995 to 2005. Approval counts came from the Food and Drug Administration. The comparison tests whether money follows need. Misalignment between funding and burden is a policy question, not just a budget one. Their tallies give reformers concrete numbers to argue from.
Catalog record
| CREATOR | E. Ray Dorsey, Joel P. Thompson, Melisa Carrasco et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007015